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Abstract: Aggregatibacter actinomycetemcomitans is an oral pathogen and etiologic agent 
of  localized  aggressive  periodontitis.  The  bacterium  is  also  a  cardiovascular  pathogen 
causing infective endocarditis. A. actinomycetemcomitans produces leukotoxin (LtxA), an 
important  virulence  factor  that  targets  white  blood  cells  (WBCs)  and  plays  a  role  in 
immune evasion during disease. The functional receptor for LtxA on WBCs is leukocyte 
function antigen-1 (LFA-1), a -2 integrin that is modified with N-linked carbohydrates. 
Interaction between toxin and receptor leads to cell death. We recently discovered that 
LtxA  can  also  lyse  red  blood  cells  (RBCs)  and  hemolysis  may  be  important  for 
pathogenesis of A. actinomycetemcomitans. In this study, we further investigated how LtxA 
might  recognize  and  lyse  RBCs.  We  found that, in  contrast  to  a related toxin,  E. coli  
-hemolysin, LtxA does not recognize glycophorin on RBCs. However, gangliosides were 
able to completely block LtxA-mediated hemolysis. Furthermore, LtxA did not show a 
preference  for  any  individual  ganglioside.  LtxA  also  bound  to  ganglioside-rich  C6  rat 
glioma cells, but did not kill them. Interaction between LtxA and C6 cells could be blocked 
by gangliosides with no apparent specificity. Gangliosides were only partially effective at 
preventing LtxA-mediated cytotoxicity of WBCs, and the effect was only observed when a 
high  ratio  of  ganglioside:LtxA  was  used  over  a  short  incubation  period.  Based  on  




the  results  presented  here,  we  suggest  that  because  of  the  similarity  between  
N-linked sugars on LFA-1 and the structures of gangliosides, LtxA may have acquired the 
ability to lyse RBCs. 
Keywords: erythrocytes; toxin; periodontal disease; endocarditis; RTX toxin 
 
1. Introduction  
Aggregatibacter actinomycetemcomitans is a gram negative oral bacterium that can cause localized 
aggressive periodontitis in adolescents (LAP) [1–3]. The bacterium is also part of the normal oral flora 
in  many  healthy  individuals  [4,5].  The  disease  occurs  predominantly  in  African  Americans  and 
approximately 70,000 adolescents develop the disease in the U.S. per year [6]. LAP is a destructive 
form of periodontitis that affects the central incisors and first molars, and LAP results in the rapid loss 
of bone and periodontal ligament surrounding the teeth. When untreated, patients who suffer from  
LAP  often  lose  their  affected  teeth.  In  addition  to  being  an  important  oral  pathogen,  
A.  actinomycetemcomitans  is  part  of  the  HACEK  group  of  bacteria  (Haemophilus  spp.,  
A.  actinomycetemcomitans,  Cardiobacterium  hominis,  Eikenella  corrodens,  and  Kingella  kingae) 
implicated in infective endocarditis (IE) [7,8] and A. actinomycetemcomitans is reported to be the 
HACEK organism involved most often in IE [9]. 
A. actinomycetemcomitans produces numerous virulence factors including leukotoxin (LtxA), which 
targets human and Old World primate white blood cells (WBC; reviewed recently in [10]). LtxA is an 
~114 kDa secreted protein [11] and is a member of the repeats in toxin (RTX) family of bacterial 
toxins.  Other RTX toxins  include  Escherichia  coli HlyA, Bordetella pertussis CyaA, Mannheimia 
haemolytica LktA, Actinobacillus pleuropneumoniae Apx toxins, and Vibrio cholerae RtxA [12]. Like 
HlyA and CyaA, LtxA has been shown to be modified with fatty acids linked to internal lysine residues 
and this modification is required for activity [13]. LtxA is believed to play an important role in immune 
evasion by selectively depleting host WBCs that target the bacterium.  
The WBC receptor for LtxA is leukocyte function antigen-1 (LFA-1) [14]. LFA-1 is a 2-integrin 
composed  of  the  subunits  CD11a  and  CD18.  These  molecules  are  modified  with  N-linked 
oligosaccharides [15] and can exist in at least two different functional states [16,17]. After binding to 
LFA-1, LtxA causes a signaling cascade that results in apoptosis when used at low concentrations. 
While the mechanism has not been completely deciphered, LtxA appears to intoxicate cells via an 
apoptotic pathway that involves the mitochondria [18]. However, at high concentrations (greater than  
5 g/mL), LtxA kills cells very rapidly by necrosis. We recently reported that LtxA preferentially kills 
cells  with  activated  LFA-1  [19].  Thus,  rather  than  killing  all  WBCs  non-specifically,  
A. actinomycetemcomitans LtxA targets immune cells that are most immunocompetent and effective at 
eliminating microbial pathogens.  
Several years ago, we discovered that LtxA could also lyse red blood cells (RBCs) from a variety of 
species including human, sheep, and horse [20]. RBCs do not express LFA-1, and so it is not known 
how LtxA interacts with these cells. The concentration of LtxA required for hemolysis of RBCs was 




number of receptors [20]. We also found that free iron repressed the secretion of LtxA from bacteria, 
which suggested a role for hemolysis in iron acquisition [21]. Because there is no available free iron in 
the host, pathogens have evolved numerous mechanisms of releasing and sequestering iron often in the 
form  of  heme.  Coupling  LtxA-mediated  hemolysis  to  other  iron  acquisition  mechanisms  may  be 
important for survival and persistence of A. actinomycetemcomitans in the host.  
Other  RTX  leukotoxins  have  also  been  shown  to  possess  hemolytic  activity,  including 
M. haemolytica LktA [22]. Cortajarena et al. [23] previously reported that another RTX toxin, E. coli  
-hemolysin, recognizes glycophorin on the surface of RBCs, which results in hemolysis. Because of 
our recent observation that LtxA has hemolytic properties, we further investigated a potential RBC 
surface component that is recognized by the toxin. We report here that LtxA does not use glycophorin 
as a receptor, but instead is blocked by and possibly interacts with gangliosides, which are lipid-sugar 
molecules expressed on the surfaces of cells. 
2. Materials and Methods 
2.1. Cells 
HL-60 (CCL-240), THP-1 (TIB-202), K562 (CCL-243) (human leukemia cell lines) and C6 rat glioma 
cells  (CCL-107)  were  obtained  from  ATCC  (Manassas,  VA).  HL-60,  THP-1,  and  K562  cells  were 
maintained in RPMI 1640 medium with 10% fetal bovine serum (Life Technologies, Carlsbad, CA) at  
37  °C ,  5%  CO2.  Cells  were  grown  for  several  days  until  cell  concentration  reached  approximately  
1.0 ×  10
6 cells/mL. Rat glioma C6 cells were grown in Hams Nutrient Mixture F-12 (Fisher Scientific, 
Pittsburgh,  PA)  with  15%  horse  serum,  2.5%  fetal  bovine  serum.  A.  actinomycetemcomitans  strain 
NJ4500 was used for LtxA purification and was grown as described [24]. 
2.2. Isolation of Human RBCs 
Human blood from a healthy volunteer was collected into a Vacutainer tube containing heparin 
sulfate (Becton-Dickinson, Franklin Lakes, NJ). Whole blood was centrifuged at 250 ×  g at 4 ° C for  
5 minutes to collect RBCs. The RBCs were washed 3–4 times in PBS until the supernatant was clear. 
One hundred microliters of washed RBCs was added to 3.9 mL PBS to yield a 2.5% RBC suspension. 
This mixture was used for all RBC studies described here. Experiments involving fresh blood from 
human subjects were approved by the UMDNJ Institutional Review Board (IRB). All human subjects 
gave informed consent to participate. 
2.3. Preparation of LtxA and LtxA-FITC  
Leukotoxin  (LtxA)  was  purified  from  culture  supernatants  of  A.  actinomycetemcomitans  strain 
NJ4500  as  previously  described  [24,25].  Briefly,  culture  supernatants  were  filtered  and  then 
ammonium sulfate precipitated to isolate protein. The ammonium sulfate pellet was then resuspended 
in LtxA buffer (20 mM Tris-HCl, pH 6.8, 250 mM NaCl, and 0.2 mM CaCl2) and passed over a 
Sephadex G-100 size exclusion column. Individual fractions were assayed for total protein content and 




LtxA-FITC was prepared using the FITC (fluorescein 5-isothiocyanate) labeling kit (Thermo Scientific, 
Rockford, IL) as described by the manufacturer. 
2.4. Ganglioside Blocking Assays 
Purified  bovine  gangliosides  (Sigma-Aldrich,  St.  Louis,  MO)  were  diluted  to  the  indicated 
concentrations  in  water  and  then  filtered  prior  to  use.  Ganglioside  (6  μL)  was  mixed  with  LtxA  
(15 μL; 0.2 mg/mL unless otherwise indicated) and incubated at room temperature for 20 minutes prior 
to adding to cells. The ganglioside-LtxA mixture was then added to cells (400 μL) and incubated at  
37 °C  for 24 hours unless otherwise indicated.  
2.5. Flow Cytometry  
RBCs  were  stained  with  phycoerythrin  (PE)-labeled  anti-glycophorin  (clone  HIR2)  antibody 
(CD235ab; Biolegend, San Diego, CA) by mixing 100 μL RBCs with 20 μL of a 1:10 dilution of the 
antibody.  Cells  were washed three times in  PBS and then resuspended in  600  μl  PBS. To assess  
LtxA-FITC  binding  to  C6  glioma  cells,  LtxA-FITC  (15  μL;  0.2  mg/mL)  was  pre-incubated  with 
ganglioside  (6  μL)  for  15  minutes  on  ice  and  then  the  mixture  was  added  to  0.1  mL  C6  cells  
(10
6 cells/mL), incubated for 30 minutes on ice, and then washed three times in PBS. Samples (at least 
10,000 cells/run) were analyzed with a FACSCalibur instrument (BD Biosciences, Franklin Lakes, NJ) 
and data was analyzed using FlowJo software (Ashland, OR). 
2.6. Cytotoxicity Assays 
To determine the cytotoxic effect of LtxA on non-RBCs, 0.1 mL cells (~10
6 cells/mL) were mixed 
with  purified  LtxA  at  various  concentrations.  The  mixture  was  incubated  at  37  °C ,  5%  CO2  for  
24 hours unless otherwise noted. Cellular viability (ATP production) was then determined using the 
CellTiter-Glo luminescent cell viability assay (Promega, Madison, WI) according to the manufacturer’s 
instructions.  Plates  were  read  in  a  Synergy  HT  plate  reader  in  the  luminescence  mode  (Bio-Tek, 
Winooski, VT). For toxicity of RBCs, 0.1 mL cells were mixed with LtxA (8 μg/mL) and lysis was 
measured by detection of released hemoglobin. After 24-hour incubation, RBCs were removed by 
centrifugation and the absorbance of the supernatant at 450 nm was assayed on a Synergy HT plate 
reader. One hundred percent cell lysis was determined by resuspending RBCs in distilled water.  
2.7. Statistical Analysis 
Data was analyzed using a Student’s t-test to test for no differences between ganglioside-treated and 
ganglioside-untreated samples. P values of <0.05 were considered significant. 
3. Results  
3.1. LtxA Does Not Use Glycophorin as a Receptor  
It was previously reported that E. coli -hemolysin can use glycophorin, a sialoglycoprotein, on the 




RBCs. We first tested if anti-glycophorin antibody that reacts with both glycophorin A and B could 
block LtxA-mediated hemolysis. RBCs were pre-incubated in anti-glycophorin antibody for 30 minutes 
on ice, washed, and then mixed with LtxA. We found that anti-glycophorin antibody did not block 
hemolysis by LtxA (Figure 1A). Two different monoclonal antibody clones were tested in these studies 
yielding  identical  results  (clones  HIR2  and  E3).  In  contrast,  anti-LFA-1  antibody  does  block  
LtxA-mediated killing of WBCs [13,14]. We next asked if LtxA could block anti-glycophorin antibody 
from binding to RBCs. We performed flow cytometry to assay antibody binding to the surface of 
RBCs. Pre-incubation of RBCs with LtxA at 4 °C  (a temperature that prevents LtxA from lysing cells) 
for 30 minutes reproducibly had no effect on anti-glycophorin antibody binding to RBCs (Figure 1B). 
Thus, these results suggest that LtxA does not use glycophorin as a RBC receptor. 
Figure 1. Effect of glycophorin and LtxA on RBCs. (a) RBCs were treated with water 
(100%  lysis),  LtxA  buffer  (background  lysis),  LtxA,  or  first  pre-treated  with  
anti-glycophorin antibody (ab) and then LtxA. Lysis was measured by detecting released 
hemoglobin  in  the  supernatant  at  450  nm.  The  data  shown  is  representative  of  
three independent experiments. (b) Flow cytometry of RBCs stained with anti-glycophorin 
antibody alone or after pre-treatment with LtxA. The shift in signal to the right represents 
cells that are stained with anti-glycophorin antibody. The data shown is representative of  
three independent experiments. 
 
3.2. Gangliosides Block LtxA-Mediated Hemolysis 
We  screened  a  panel  of  carbohydrates  and  carbohydrate-containing  molecules  to  identify 
compounds that might block LtxA-mediated hemolysis. We found that only two of the compounds, 
gangliosides GM1 and GD1b, were able to block hemolysis nearly completely (Table 1). The screen 
was  performed  three  independent  times  to  confirm  these  results.  Other  bacterial  toxins,  including 
cholera toxin, E. coli heat-labile toxins, tetanus toxin, botulinum toxin, pertussis toxin, and shiga toxin, 
have been shown to use gangliosides as cellular receptors [26–29]. Gangliosides are glycosphingolipids 
found on the surfaces of many vertebrate cell types, especially RBCs and brain cells, and play a role in 
signaling and membrane protein regulation [30]. They consist of a lipid ceramide moiety attached to an 
oligosaccharide chain that contains at least one sialic acid residue (Figure 2). We next tested several 
purified gangliosides for their ability to block LtxA-mediated hemolysis. LtxA was pre-incubated in 




to allow hemolysis to occur. Figure 3A shows that five different gangliosides (GM3, GM1, GD1a, 
GD1b, and GT1b) were able to completely prevent LtxA-mediated hemolysis. The blocking effect was 
dose-dependent as shown in Figure 3B. In contrast, asialo GM1, lacking the sialic acid side group, was 
unable to fully block hemolysis. This result suggests that sialic acid is required for LtxA to interact 
with RBCs. Therefore, we also tested if sialic acid alone was sufficient to block hemolysis (Figure 3A). 
We found that sialic acid, even at high concentrations (15 μg/mL), was unable to completely prevent 
LtxA from lysing RBCs (Figure 3A). These results show that collectively, for LtxA recognition of 
RBCs, sialic acid is a necessary component of gangliosides, but alone is not sufficient to block lysis. 
To confirm that the gangliosides were binding to LtxA and not something on the surfaces of RBCs, we 
first pre-incubated RBCs with the gangliosides (GM3, GM1, GD1a, and GD1b). The RBCs were then 
washed, mixed with LtxA and incubated at 37 °C  for 24 hours. We found that pre-incubation of RBCs 
with gangliosides did not block LtxA from lysing RBCs, indicating that the gangliosides are acting on 
LtxA (data not shown). 
Figure 2. Structures of gangliosides and protein-linked carbohydrates. GD3, GM1, GD1a, 
GD1b, GT1b, and asialoGM1 are gangliosides. Cer, ceramide; R, complex-type sugar chain 
as described in [15]. 




Figure 3. Gangliosides block LtxA-mediated lysis of RBCs. (A) LtxA (7.5 μg/mL) was 
pre-incubated with sugars (15 μg/mL or 1.5 μg/mL) noted on the x-axis for 20 minutes and 
then added to RBCs. RBCs were also treated with LtxA buffer to represent background 
lysis. Experiment was performed in triplicate and standard deviation error bars are shown. 
GM3, GM1, GD1a, GD1b, and GT1b all caused significant inhibition of LtxA-mediated 
lysis (P < 0.05). (B) Gangliosides block hemolysis by LtxA in a dose-dependent manner. 
Results are the average from three independent experiments. LtxA buffer caused relative 
background lysis of approximately 0.1. All values are relative to LtxA alone (set to 1.0). 
 
Table  1.  Compounds  that  were  screened  for  their  ability  to  block  LtxA-mediated 
hemolysis.  +  represents  greater  than  90%  blocking  of  LtxA-  mediated  hemolysis;  
- represents less than 10% blocking of LtxA- mediated hemolysis. 
Compound  Blocking 
-lactose  - 
D (-) fructose  - 
D (+) galactose  - 
D-glucose  - 
D-maltose  - 
D-arabinose  - 
D-ribose  - 
Sucrose  - 
D (+) mannose  - 
D (+) xylose  - 
N-acetylmuramic acid  - 
Ganglioside GM1  + 
Ganglioside GD1b  + 
3.3. LtxA Binds to Gangliosides on Glioma Cells  
Studies with other bacterial toxins that bind gangliosides have employed glioma cell lines, such as 
rat glioma C6 cells, because they are enriched in gangliosides on their surfaces [27]. Because glioma 
cells should not be killed by LtxA, we could study binding of LtxA without the complications of 




a 24-hour incubation with LtxA, the viability of C6 cells was not affected by any concentration of toxin 
tested  in  contrast  to  HL-60  cells  (Figure  4A).  To  assay  binding  of  LtxA  to  cells,  we  generated 
fluorescently-tagged LtxA (see Materials and Methods). Similar studies have been carried out using a 
FITC-labeled version of cholera toxin [31,32]. Modified LtxA (designated LtxA-FITC) was still active 
against HL-60 cells, indicating that covalent modification did not adversely affect activity of the toxin 
(data not shown). We next measured binding of the toxin to cells using flow cytometry (Figure 4B). 
LtxA-FITC stained C6 cells strongly (Figure 4B), but not K562 cells (data not shown), which lack 
LFA-1expression  [14,19].  More  than  90%  of  the  cells  stained  with  LtxA-FITC.  However,  
pre-incubation of LtxA-FITC with gangliosides GM3, GM1, GD3, and GD1a decreased staining of C6 
cells (Figures 4B and 4C). Pre-incubation resulted in an approximately 80% decrease in staining per 
cell. These results were highly reproducible. 
Figure 4. Interaction between LtxA-FITC and C6 glioma cells. (A) C6 or HL-60 cells were 
mixed  with  varying  amounts  of  LtxA  and  then  incubated  for  24  hours.  Viability  was 
measured  using  the  CellTiter-Glo  viability  assay.  The  experiment  was  performed  in 
triplicate  and  standard  deviation  error  bars  are  shown  (P  <  0.05).  (B)  Detection  of  
LtxA-FITC binding to C6 cells using flow cytometry. Cells were stained with LtxA-FITC 
alone or LtxA-FITC that was pre-incubated (20 minutes) with the ganglioside noted. The 
left-most bar displays the percent of cells that are negative and the right-most bar represents 
percent of cells positive for staining with LtxA-FITC. The values on the x-axis represent 
fluorescence intensity. Results are representative of three experiments. (C) Histogram of 
the data shown in (B) from three experiments. * represents P < 0.05. 




3.4. Gangliosides Inefficiently Block LtxA-Mediated Killing of WBCs  
LtxA  is  highly  specific  for  human  and  Old  World  primate  WBCs.  We  thus  determined  if 
gangliosides could also block LtxA-mediated killing of THP-1 WBCs. We found that, in contrast to 
lysis of RBCs, gangliosides GM1 and GM3 were not highly effective at blocking WBC cytotoxicity 
even though the ratio of GM1 molecules to LtxA molecules was 150:1 (Figure 5). Partial blocking was 
observed at lower doses of LtxA (~100 ng/mL; GM1 molecules to LtxA molecules ~7000:1); however, 
at higher concentrations of toxin, the gangliosides were largely ineffective at inhibiting LtxA-mediated 
toxicity. In addition, these experiments with THP-1 cells had to be reduced to three hours (RBC assays 
were performed for 24 hours); otherwise, LtxA overcame the inhibitory effects of the gangliosides after 
longer incubation times (data not shown). Thus, gangliosides can partially block killing of WBCs by 
LtxA only when the ratio of ganglioside to LtxA is high. 
Figure 5. Gangliosides inefficiently block LtxA-mediated toxicity of WBCs. THP-1 cells 
were treated for three hours with LtxA alone or LtxA pre-incubated with ganglioside GM1 
or  GM3.  The  experiment  was  performed  three  times  and  the  averages  and  standard 
deviations are shown. * represents P < 0.05. 
 
4. Discussion  
We show here that RBC lysis by A. actinomycetemcomitans LtxA is efficiently blocked by soluble 
gangliosides.  Gangliosides  also  abrogate  binding  of  LtxA-FITC  to  ganglioside-rich  glioma  cells. 
Numerous bacterial toxins utilize gangliosides as cellular receptors on various cell types. These toxins 
are highly selective for specific gangliosides. For example, cholera toxin and E. coli heat-labile toxin 
bind to GM1, botulinum toxin to GT1b and GQ1b, and pertussis toxin to GD1a [26]. In contrast, based 
on the work presented here, LtxA does not show a preference for any specific ganglioside. To our 
knowledge, only one other bacterial toxin, Clostridium perfringens  toxin, has been shown to interact 
with a ganglioside on RBCs, namely GM2 [33]. 
While  gangliosides  effectively  prevented  LtxA-mediated  lysis  of  RBCs,  they  were  much  less 
effective at protecting WBCs from LtxA. LFA-1, the WBC receptor for LtxA, is a heavily glycosylated 
membrane protein [15]. Asada et al. [15] reported that ~60% of the oligosaccharide moieties that 
modify LFA-1 have the terminal structure: sialic acidgalactoseN-acetylglucosamine (Figure 2). 
Interestingly, this terminal sugar structure found on LFA-1 is strikingly similar to the gangliosides that 




2  integrin  receptors  through  their  N-linked  oligosaccharide  chains  and  suggest  that  interaction 
between toxin and oligosaccharide represents the initial binding step. They showed that treatment of 
Jurkat T-cells with glycosidases rendered these cells more resistant to killing by RTX toxins, including 
LtxA. However, LtxA was still able to kill glycosidase-treated cells, but less efficiently than untreated 
cells. This result suggests that the deglycosylation was not complete or that LtxA can still interact with 
deglycosylated LFA-1, albeit less efficiently. WBCs have been reported to also express gangliosides on 
their surfaces [35,36]. However, cell lines that do not express LFA-1 (CD11a, CD18, or both) are 
completely resistant to LtxA-mediated toxicity [14,19], indicating that LtxA does not function through 
gangliosides on WBCs. This result is similar to the effect of LtxA on C6 glioma cells, which are 
recognized by LtxA but not killed. Thus, it appears that gangliosides do not act as potential functional 
receptors on cells except RBCs. 
Based on several lines of evidence, we hypothesize that LtxA originally evolved as a toxin to target 
the immune system by interacting with LFA-1, but because of the similarities between the N-linked 
oligosaccharides of LFA-1 and gangliosides on the surface of RBCs, the toxin “gained” the ability to 
recognize  and  lyse  RBCs.  First,  all  of  the  sialidated  gangliosides  we  tested  were  able  to  block  
LtxA-mediated hemolysis equally well with no apparent preference. All other bacterial toxins that 
interact with ganglioside receptors show strong preference for one or two gangliosides [26]. Second, 
gangliosides were only partially effective at blocking LtxA-mediated killing of WBCs (THP-1 cells) at 
low doses of LtxA and short incubation times. At high LtxA doses, blocking was not apparent. Third, 
when LtxA bound to C6 glioma cells via gangliosides, there was no subsequent toxicity or cellular 
changes, even at high doses after 24 hours. Interaction between other toxins and gangliosides always 
leads to noticeable downstream effects, especially, cell death.  
Interaction  between  RTX  toxins  and  cellular  receptors,  such  as  LFA-1,  leads  to  membrane 
disruption  [37–39]  and  cellular  signaling  that  ultimately  results  in  cell  death  [40–43].  However, 
because RBCs lack LFA-1 and there is unlikely to be an intracellular signaling cascade activated by 
LtxA in RBCs, we suggest that interaction between LtxA and RBC gangliosides results in disruption of 
the  membrane,  which  leads  to  cell  lysis.  Following  interaction  with  LFA-1  on  WBCs,  LtxA  is 
proposed  to  undergo  significant  conformational  changes  that  result  in  membrane  insertion  of  the  
toxin  [39].  Thus,  contact  between  LtxA  and  gangliosides  may  result  in  a  similar  change  in 
conformation that allows LtxA to insert into and disrupt RBC membranes. Further biochemical studies 
will be required to test our hypothesis. 
In conclusion, we demonstrate that gangliosides can block hemolysis by a toxin from an important 
oral pathogen. Our data and knowledge of other bacterial toxins suggest that gangliosides may act as a 
RBC receptor for LtxA. For individuals with HACEK-causing IE, the most common route of infection 
is  through the oral  cavity since the HACEK bacteria are part of the normal  oro-pharyngeal flora.  
A.  actinomycetemcomitans  can  be  found  on  infected  heart  tissue  where  it  exists  as  vegetative  
growths [9]. This indicates that A. actinomycetemcomitans has the ability to enter the blood stream, 
evade host immune defenses, colonize heart tissue, and persist in this environment. Furthermore, one 
of the clinical symptoms of IE is marked anemia, and hemolysis is considered to be an important 




may be a crucial step in the pathogenic process and understanding this interaction could lead to novel 
therapeutic modalities.  
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